GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (17)
  • 1
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 25, No. 21 ( 2019-11-01), p. 6368-6381
    Abstract: More than 70% of patients with breast cancer present with node-negative disease, yet all undergo surgical axillary staging. We aimed to define predictors of nodal metastasis using clinicopathological characteristics (CLINICAL), gene expression data (GEX), and mixed features (MIXED) and to identify patients at low risk of metastasis who might be spared sentinel lymph node biopsy (SLNB). Experimental Design: Breast tumors (n = 3,023) from the population-based Sweden Cancerome Analysis Network–Breast initiative were profiled by RNA sequencing and linked to clinicopathologic characteristics. Seven machine-learning models present the discriminative ability of N0/N+ in development (n = 2,278) and independent validation cohorts (n = 745) stratified as ER+HER2−, HER2+, and TNBC. Possible SLNB reduction rates are proposed by applying CLINICAL and MIXED predictors. Results: In the validation cohort, the MIXED predictor showed the highest area under ROC curves to assess nodal metastasis; AUC = 0.72. For the subgroups, the AUCs for MIXED, CLINICAL, and GEX predictors ranged from 0.66 to 0.72, 0.65 to 0.73, and 0.58 to 0.67, respectively. Enriched proliferation metagene and luminal B features were noticed in node-positive ER+HER2− and HER2+ tumors, while upregulated basal-like features were observed in node-negative TNBC tumors. The SLNB reduction rates in patients with ER+HER2− tumors were 6% to 7% higher for the MIXED predictor compared with the CLINICAL predictor accepting false negative rates of 5% to 10%. Conclusions: Although CLINICAL and MIXED predictors of nodal metastasis had comparable accuracy, the MIXED predictor identified more node-negative patients. This translational approach holds promise for development of classifiers to reduce the rates of SLNB for patients at low risk of nodal involvement.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 69, No. 21 ( 2009-11-01), p. 8455-8462
    Abstract: The usurping of translational control by sustained activation of translation initiation factors is oncogenic. Here, we show that the primary negative regulators of these oncogenic initiation factors—the 4E-BP protein family—operate as guardians of a translational control checkpoint in lung tumor defense. When challenged with the tobacco carcinogen 4-(methylnitrosamino)-I-(3-pyridyl)-1-butanone (NNK), 4ebp1−/−/4ebp2−/− mice showed increased sensitivity to tumorigenesis compared with their wild-type counterparts. The 4E-BP–deficient state per se creates pro-oncogenic, genome-wide skewing of the molecular landscape, with translational activation of genes governing angiogenesis, growth, and proliferation, and translational activation of the precise cytochrome p450 enzyme isoform (CYP2A5) that bioactivates NNK into mutagenic metabolites. Our study provides in vivo proof for a translational control checkpoint in lung tumor defense. [Cancer Res 2009;69(21):8455–62]
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2009
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3575-3575
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3575-3575
    Abstract: Introduction The prostate is an organ where the dual actions of estrogen receptors (ERα and ERβ)are just beginning to be understood and appreciated in a physiological context. Steroid receptors can act outside of the nucleus by interacting with cytoplasmic or membrane bound proteins and activating or inhibiting signaling pathways in a ligand dependent or independent manner. However, our understanding of this non-nuclear activity remains partial. Here, we attempt to uncover how estrogens regulate post-transcriptional gene expression programs in prostate cancer. The rationale for studying impacts on post-transcriptional gene expression programs downstream of a transcription factor is that there is often no direct correlation between the level of an mRNA and the corresponding protein product. Additionally, several intracellular signaling pathways affected by estrogen signaling (e.g MAPK and PI3K pathways) directly regulate gene expression post-transcriptionally. One post-transcriptional mechanism that is tightly regulated by various intracellular signaling pathways is mRNA translation initiation - a highly controlled step that is regulated on multiple levels and is commonly deregulated in cancer. Many factors acting on mRNAs in cis and/or in trans, including RNA-binding proteins, RNA secondary structures or modifications of the cap structure by methylation can have strong impact on the efficiency of mRNA translation. Thus, estrogen signaling, by directly and indirectly affecting intracellular signaling can potentially regulate translational activity of its transcriptional targets. Approach We used prostate derived cell lines to assess how estrogens regulate proliferation and survival as a function of their ability to modulate transcription and translation. We performed polysome-microarray approach where the cytoplasmic mRNA population is separated based on the number of associated ribosomes followed by quantification of mRNA levels in pools of actively translating mRNAs. Using prostate cell lines, epithelial and stromal in origin, we first characterized the level of transcription and translation in unstimulated conditions to obtain a snapshot of the translational activity of each mRNA in baseline conditions. Secondly, we tested the impact on transcription and translation following stimulation for 2 hours with estradiol or with an ERβ-specific agonist (8β-VE2). We are currently validating ERα/β translational targets and identifying regulatory RNA sequences that enable ER-induced translational control. Conclusion We endeavor to determine how the gene expression programs regulated by ERα and ERβ are integrated at the transcriptional and translational level to direct proliferation, growth and survival in prostate tumors. Citation Format: Luc Furic, Ola Larsson, Ivan Topisirovic, Mark Frydenberg, John Pedersen, Gail Risbridger. Integration of estradiol signaling at the translational and transcriptional level in prostate cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3575. doi:10.1158/1538-7445.AM2013-3575
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2004
    In:  Cancer Research Vol. 64, No. 2 ( 2004-01-15), p. 482-489
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 64, No. 2 ( 2004-01-15), p. 482-489
    Abstract: Replicative senescence limits the number of times primary cells can divide and is therefore regarded as a potential checkpoint for cancer progression. The majority of studies examining changes of gene expression upon senescence have been made with stationary senescent cells. We wanted to study the transition from normal growth to senescence in detail and identify early regulators of senescence by analyzing early changes in global gene expression, using Affymetrix microarrays. For this purpose, we used a murine epithelial senescence model, where senescence is abrogated by SV40 large T antigen and can be induced by using a temperature-sensitive form of SV40 large T antigen (SV40ts58). Comparisons were made to wild-type SV40 large T antigen-expressing cells and to cells expressing SV40ts58 large T antigen grown to confluence. After removal of genes that are similarly regulated in wild-type and temperature-sensitive SV40 large T antigen-expressing cells, 60% of the remaining genes were shared between cells arrested by inactivation of SV40 T antigen and by confluence. We identified 125 up-regulated and 39 down-regulated candidate genes/expressed sequence tags that are regulated upon SV40 T antigen inactivation and not during heat shock or confluence and classified these based on their kinetic profiles. Our study identified genes that fall into different functional clusters, such as transforming growth factor-β-related genes and transcription factors, and included genes not identified previously as senescence associated. The genes are candidates as early regulators of the senescence checkpoint and may be potential molecular targets for novel anticancer drugs.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2004
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 22_Supplement ( 2021-11-15), p. PO-088-PO-088
    Abstract: Molecular profiling of Pancreatic Ductal Adenocarcinoma (PDA), based on transcriptomic analyses, identifies two main prognostic subtypes (basal-like and classical), but does not allow personalized first-line treatment. To date, tumors have not been profiled based on protein synthesis rates, yet the step of mRNA translation is highly dysregulated in both PDA cancer cells and their microenvironment. We aim at assessing whether quantification of mRNA translation could provide a distinct perspective on PDA and identify novel tumor subtypes. Using a collection of twenty-seven pancreatic Patient-Derived Xenografts (PDX), we performed transcriptome-wide analysis of translated mRNA (translatome). Unsupervised bioinformatics analysis allowed PDA tumors classification according to mRNA translation rate. PDX-derived cancer cells as well as common PDA cell lines were used to functionally characterize newly identified subtype. Independent component analysis revealed a new tumor subtype harboring a low protein synthesis rate, but associated with a robust translation of mRNAs encoding effectors of the integrated stress response (ISR), including the transcription factor ATF4. Functional characterization of the “ISR-activated” human cancer cells revealed a high resistance to drugs, low autophagic capacities, and importantly, metabolic impairments in the serine synthesis and transsulfuration pathways. Therefore, the drug-resistant cancer cell phenotype showing auxotrophy to both serine and cysteine may be amenable to targeted therapy. Overall, our study highlights profiling of mRNA translation in cancer as an underexplored avenue for identification of previously unrecognized subtypes together with potential treatments. Citation Format: Sauyeun Shin, Remy Nicolle, Mehdi Liauzun, Jacobo Solorzano, Alexia Brunel, Christine Jean, Remi Samain, Jerôme Raffenne, Cindy Neuzillet, Carine Joffre, Stephane Rocci, Juan Iovanna, Nelson Dusetti, Ola Larsson, Stephane Pyronnet, Corinne Bousquet, Yvan Martineau. Classification based on efficiency of mRNA translation reveals a metabolically-dependent subtype of pancreatic cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-088.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 6_Supplement ( 2017-03-15), p. A31-A31
    Abstract: Protein synthesis is one of the most energy consuming process in the cell. Oncogenic kinases (e.g. EGFR/HER2, BCR/ABL and BRAF) play a central role in reprogramming translation and energy metabolism in neoplasia, whereby cancer cells must provide sufficient ATP to support increased levels of protein synthesis required for neoplastic growth. The downstream mechanisms that link translational machinery and energy homeostasis in cancer, however, remain largely unknown. We found that widely used anti-diabetics (biguanides) abrogate adaptations to EGFR/HER2 inhibitor-induced energetic stress, which results in synergistic anti-neoplastic effects both in vitro and in vivo. In turn, breast cancer cells in which 4E-BP1/2 expression was abrogated by CRISPR were partially resistant to the combination of EGFR/HER2 inhibitors and biguanides. This was paralleled by the inability of the drugs to inhibit the eIF4F complex assembly and translation of mRNAs encoding important metabolic regulators including those involved in serine biogenesis (PHGDH, PSAT1) and one carbon metabolism (MTHFD1L). Comparable results were observed when BRAF and BCR/ABL inhibitors were combined with biguanides, which suggests that translational regulation of metabolic genes via the mTORC1/4E-BE/eIF4E pathway plays a major role in energy stress response in cancer. Together our findings demonstrate that the eIF4F complex is an important mediator of metabolic adaptation in response to the combination of biguanides and clinically-used kinase inhibitors and suggest that the efficiency of such anti-cancer strategies are dependent on the integrity of the translation initiation machinery. Citation Format: Laura Hulea, Marie Cargnello, Simon-Pierre Gravel, Young Im, Shannon McLaughlan, Yunhua Zhao, Jenna Ching, Yutian Cai, Ola Larsson, Michael Ohh, Josie Ursini-Siegel, Julie St-Pierre, Michael Pollak, Ivan Topisirovic. eIF4F links translation to energy stress response in cancer. [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr A31.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P3-01-26-P3-01-26
    Abstract: Background: At time of diagnosis of metastatic disease, a biopsy of the metastatic lesion is recommended to confirm diagnosis and as a basis for systemic treatment decision.Numerous papers have reported discrepancy between routinely used biomarker status of the primary tumor and corresponding metastases in a relatively large proportion of patients, but less is known about gene expression profiles throughout tumor progression. Differences between biomarker status of the primary tumor lesion and its metastasis could be a major cause of treatment failure, and the molecular alterations that occur during tumor progression are still incompletely described. The main objective of this study was to use tumor specimens collected from a prospective observational trial to determine the PAM50 breast cancer intrinsic subtype in matched pairs of tumor samples from primary tumor (PT), synchronous lymph node metastases (LNMs), and distant metastases (DMs), to investigate if subtype classification changes during tumor progression, and the putative implication of a shift in inherence on prognosis. Materials and Methods: RNA was isolated from archival formalin-fixed, paraffin-embedded tumor tissue from newly diagnosed metastatic breast cancer patients (N=156) enrolled in the CTC-MBC trial (NCT01322893), and run with the NanoString Breast Cancer 360 assay on the NanoString nCounter Sprint Profiler. PAM50 breast cancer intrinsic subtyping analysis was completed at NanoString, and the statistical analysis at Lund University. Exact McNemar tests and exact tests of symmetry were used to compare subtype inherence at two locations, i.e. matched pairs of PTs and LNMs or DMs. Results: RNA from 143 patients was evaluable. A PAM50 breast cancer intrinsic subtype could be assigned to 124 PT samples, 68 synchronous LNMs and 76 DMs (Table 1), of which 59 and 63 had paired data, respectively. The evidence for a difference in PAM50 breast cancer intrinsic subtype between matched pairs (PT and LNM; PT and DM) was generally strong (Table 2). A PAM50 conversion was seen in 21/59 (36%) cases considering the luminal A vs non-luminal A subtype between matched pairs of PT and LNM, 17/21 (81%) of which changed from luminal A to non-luminal A subtype (P=0.007). In matched pairs of PT and DM a PAM50 conversion was seen in 27/63 (43%) cases comparing the luminal A vs non-luminal A subtype, 25/27 (93%) of which changed from luminal A to non-luminal A subtype (P & lt;0.001). Conclusion: The present study shows that PAM50 breast cancer intrinsic subtype is not stable throughout tumor progression. A significant shift towards a non-luminal A subtype profile was observed in both LNMs and DMs. The shift towards a non-favorable subtype from PT to DM confirms previous data on biomarker status, whereas the significant shift towards a non-luminal A subtype in LNM has to our knowledge not previously been described. Survival analysis is ongoing on the prognostic implication of a shift in PAM50 breast cancer intrinsic subtype. Table 1. Distribution of PAM50 breast cancer intrinsic subtype at different tumor progression stagesPAM50 subtypeIncluded N (%)Luminal A, N (%)Luminal B, N (%)HER2-enriched N (%)Basal N (%)Primary tumors12447 (38)46 (37)15 (12)16 (13)Synchrounous lymph node metastases6818 (27)37 (54)9 (13)4 (6)Distant metastases767 (9)41 (54)20 (26)8 (11) Table 2. PAM50 breast cancer intrinsic subtype concordance at different stages of tumor progressionPAM50 subtype Lymph node metastasis Luminal ALuminal BHER2-enrichedBasalTotalP *P **Luminal A131700300.0070.002Primary tumorLuminal B3152121HER2-enriched10405Basal01023 Total17336359 Distant metastasis Luminal ALuminal BHER2-enrichedBasalTotalP *P **Luminal A5167230 & lt;0.001 & lt;0.0001Primary tumorLuminal B2173123HER2-enriched00505Basal00145 Total73316763 *Exact McNemar test for Luminal A versus non-Luminal A subtype**Exact test of symmetry Citation Format: Charlotte Levin Tykjär Jörgensen, Carina Forsare, Pär-Ola Bendahl, Anna-Maria Larsson, Kristina Lövgren, Kristina Aaltonen, Sara Jansson, Lisa Rydén. Comparison of PAM50 intrinsic subtype profiles in matched primary and metastatic breast cancer samples from the CTC-MBC trial (NCT01322893) shows a significant shift towards more aggressive subtypes throughout tumor progression [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-01-26.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 67, No. 14 ( 2007-07-15), p. 6814-6824
    Abstract: Pathologic redirection of translational control by constitutive activation of eukaryotic translation initiation factor 4F (eIF4F), the cap-dependent translation initiation apparatus, is an obligatory step in oncogenesis; however, its mechanism remains undefined. Here, we simulate this pro-oncogenic state by overexpressing eIF4E, the rate-limiting component of eIF4F, in primary human mammary epithelial cells (HMECs) and examine the resultant changes in cell biology and gene expression profiles of total and polyribosome-bound mRNA genome wide. Overexpressed eIF4E rescues primary HMECs from telomere-independent growth arrest and disables checkpoints governing S-phase entry as well as apoptosis in HMECs immortalized by telomerase, imparting cells with proliferative and survival autonomy. Although the transcriptional response to increased eIF4E was modest, the translational response was large, selective, and bidirectional. In addition to translational activation of known and novel eIF4E-responsive oncogenic drivers regulating cell growth and survival, our data unveil previously unrecognized cellular defenses including translational activation of tumor suppressors, translational repression of transcripts enriched with miRNA target sites, and translational modulation of genes governing translation itself. These findings provide insight into the proneoplastic and compensatory mechanisms embedded in the oncogenic translational program. They support a model whereby deregulated eIF4E moves human epithelial cells along the cancer pathway by profoundly altering ribosomal recruitment to cancer-related transcripts, and eIF4E-modified cells counter these potentially oncogenic alterations with a compensatory translational mechanism that mitigates acquisition of malignancy. [Cancer Res 2007;67(14):6814–24]
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2007
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 20_Supplement ( 2014-10-15), p. A11-A11
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 20_Supplement ( 2014-10-15), p. A11-A11
    Abstract: Background: The current project aims to explore the possibility to use formalin fixed paraffin embedded (FFPE) samples for exome sequencing, which would open up a large collection of tissue samples for molecular studies. Usage of formalin is known to degrade and modify the DNA both during treatment and storage resulting in problems in downstream molecular analyses. The aim of the present study is to evaluate exome sequencing of FFPE samples by comparing data from FFPE normal tissue to corresponding snap frozen (SF) blood controls with focus on data output such as amount of data removed due to low sequencing quality, amount of data mapped to the genome, GC-content, and duplicate levels. Methods: In the current study we used the western Swedish biobank of neural tumors archived at the Sahlgrenska Hospital, Gothenburg. We performed exome sequencing of FFPE normal adrenal tissue samples and corresponding SF blood samples from five patients diagnosed with pheochromocytoma/paraganglioma. Two of the patients had known heterozygous germline mutations and were included to determine if these mutations could be found in both sample types. Libraries for SF samples were prepared according to protocol using Agilent Technologies SureSelect Human All Exon 50 Mb library prep kit. FFPE samples were prepared with slight modifications in the protocol, with additional PCR cycles used to increase amplification. 75 bp paired end reads were generated on Illumina HiScan SQ according to manufacturer's protocol (v.3). Results: Between 92-99% of the raw data were kept after removal of data due to low sequencing quality independent of sample type. For the SF samples 99-100% of the trimmed data mapped to the genome, the number for FFPE samples were slightly lower ranging from 87-98%. The GC content in the exome enriched DNA from FFPE and SF tissue were similar, ranging between 45-51%. Looking at the mapped data we found higher levels of duplicates in the FFPE samples compared to the SF samples, 19-78% vs. 5-15%. For one of the two patients with a known germline mutation the variant was detected at approximately the same frequency in both FFPE and SF sample (39% in FFPE vs. 44% in SF). For the other patient the variant were found at higher frequency in the FFPE sample compared to SF sample (80% vs. 50%). Conclusions: We saw no difference in amount data removed due to low sequencing quality between the five FFPE and SF samples evaluated in this study. Also, we saw only slightly lower mapping frequencies for the FFPE samples. The GC-content for both FFPE and SF samples were within the range of what's expected for exome sequencing data for libraries prepared with this kit and sequenced on Illumina HiScan SQ platform. Due to the additional PCR cycles used for FFPE samples we saw higher duplicate levels in these samples, suggesting that deeper sequencing is necessary for FFPE samples to get the same amount of unique reads as for the SF samples. A probable explanation to the higher allele frequency of the variant observed in the FFPE sample from one of the patients with a known germline mutation is the presence of contaminant tumor cells in the normal tissue sample, resulting in a shifted allele frequency. To conclude, SF samples are to prefer for exome sequencing. However, if SF material is not available FFPE tissue is a good alternative to increase the sample cohort when studying rare and complex diseases. Citation Format: Annica Wilzen, Heidi Ottesen, Anna Larsson, Bo Wangberg, Andreas Muth, Ola Nilsson, Frida Abel. Exome sequencing of FFPE material: An evaluation. [abstract]. In: Proceedings of the AACR Special Conference on Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes; Nov 3-6, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;74(20 Suppl):Abstract nr A11.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P4-01-04-P4-01-04
    Abstract: Background: Circulating tumor cells (CTCs) have repeatedly been shown to carry independent prognostic information in metastatic breast cancer (MBC). A CTC count of 5 cells per 7.5 mL blood is a generally accepted cut-off, where MBCs with & lt;5 CTCs are classified as MBCindolent and ≥5 CTCs as MBCaggressive. Furthermore, several studies have shown that the presence of CTC clusters add prognostic information to CTC count alone. Invasive lobular carcinoma (ILC) is the second most common histological breast cancer (BC) type (~10%). The vast majority of all BCs (~80%) are classified as invasive ductal carcinoma (IDC). Many distinguishing clinicopathological and genomic features have been identified between these two types, but in spite of this, current clinical management strategies and treatments are similar and mainly based on studies dominated by IDCs. The aim of this study was to explore potential differences in the distribution and prognostic significance of CTC count and CTC clusters in metastatic ILC vs. IDC, in a prospective observational study. Patients and methods: Between April 2011 and June 2016, 139 women with newly diagnosed metastatic ILC (N=28) and IDC (N=111) were included. CTCs and CTC clusters were detected, using CellSearch technology (Menarini Silicon Biosystems), at baseline (BL) before first-line systemic therapy, and during the first 6 months of follow-up (FU). The primary endpoint was progression-free survival (PFS) and the secondary endpoint overall survival (OS). Median FU time was 49 (27-93) months. Results: There was a highly significant (P & lt;0.001) difference in the median CTC count between ILC (70, range 0-2598) and IDC (2, range 0-668) at BL, and presence of CTC clusters was also higher (36% vs. 18%, P=0.07). These differences between ILC and IDC persisted in the luminal A-like subgroup. The CTC count and CTC clusters declined in both ILC (median count 4, range 0-85; clusters: 4%) and IDC (median count 0, range 0-263; clusters: 12%) after 1 month of systemic treatment, but the decline was most pronounced in ILC. Seventy-nine percent of the ILCs and 46% of the IDCs were classified as MBCaggressive (CTC ≥5) at BL (P=0.003). The prognostic value of CTC ≥5 on PFS (HR 1.5, 95% CI 0.55-4.0, P=0.44) and OS (HR 2.4, 95% CI 0.71-8.3, P=0.16) in ILC was weak, whereas significant prognostic effects were seen in IDC (PFS: HR 1.7, 95% CI 1.2-2.6, P=0.007; OS: HR 2.1, 95% CI 1.3-3.3, P=0.002). With higher cut-offs the prognostic impact of CTC count on PFS/OS was significant also in ILC (CTC ≥20: HR 3.0, 95% CI 1.3-6.8, P=0.01 / HR 3.1, 95% CI 1.2-8.3, P=0.02) (CTC ≥80: HR 3.6, 95% CI 1.5-8.8, P=0.004 / HR 5.9, 95% CI 2.0-17.8, P=0.002) and the prognostic effect in IDC remained. The presence of ≥1 CTC cluster was a negative prognostic factor significantly associated with impaired survival in ILC (PFS: HR 4.6, 95% CI 1.7-12.4, P=0.003; OS: HR 4.9, 95% CI 1.7-13.8, P=0.003), whereas the effect was weaker in IDC (PFS: HR 1.2, 95% CI 0.69-2.0, P=0.55; OS: HR 1.9, 95% CI 1.1-3.3, P=0.02). First-line systemic treatment was similar in ILC vs. IDC (endocrine 46% vs. 39% and chemotherapy 54% vs. 61%) and the overall prognosis did not differ (PFS: HR 0.89, 95% CI 0.57-1.4, P=0.59; OS: HR 0.99, 95% CI 0.60-1.6, P=0.96). Conclusions: In this study of metastatic ILC and IDC, the CTC count at BL was remarkably higher in ILCs and the presence of CTC clusters was also more common, in spite of the fact that no difference in prognosis was seen. The prognostic value of the generally accepted CTC cut-off (≥5) was clearly weaker and the presence of CTC clusters stronger in ILC vs. IDC. A higher cut-off might be more suitable in ILCs in order to better discriminate between MBCindolent and MBCaggressive forms, and CTC clusters could potentially add prognostic information. Citation Format: Ulrik Christoffer Narbe, Pär-Ola Bendahl, Kristina Aaltonen, Mårten Fernö, Carina Forsare, Charlotte Levin Tykjær Jørgensen, Anna-Maria Larsson, Lisa Rydén. The distribution and prognostic significance of circulating tumor cells are different in invasive lobular carcinoma compared to invasive ductal carcinoma of the breast [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-01-04.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...